Inhibikase Therapeutics IKT Stock
Inhibikase Therapeutics Price Chart
Inhibikase Therapeutics IKT Financial and Trading Overview
| Inhibikase Therapeutics stock price | 2.15 USD |
| Previous Close | 0.63 USD |
| Open | 0.64 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 800 |
| Day's Range | 0.62 - 0.65 USD |
| 52 Week Range | 0.44 - 1.21 USD |
| Volume | 53.32K USD |
| Avg. Volume | 187.24K USD |
| Market Cap | 19.57M USD |
| Beta (5Y Monthly) | 0.918789 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.16 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5 USD |
IKT Valuation Measures
| Enterprise Value | -5976797 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.3695651 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 137.85251 |
| Price/Book (mrq) | 0.77300614 |
| Enterprise Value/Revenue | -42.111 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Inhibikase Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.918789 |
| 52-Week Change | -27.58% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.21 USD |
| 52 Week Low | 0.44 USD |
| 50-Day Moving Average | 0.62 USD |
| 200-Day Moving Average | 0.69 USD |
IKT Share Statistics
| Avg. Volume (3 month) | 187.24K USD |
| Avg. Daily Volume (10-Days) | 46.34K USD |
| Shares Outstanding | 31.06M |
| Float | 22.71M |
| Short Ratio | 2.78 |
| % Held by Insiders | 24.62% |
| % Held by Institutions | 20.06% |
| Shares Short | 217.83K |
| Short % of Float | 0.85% |
| Short % of Shares Outstanding | 0.69% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -12825.30% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -34.18% |
| Return on Equity (ttm) | -60.31% |
Income Statement
| Revenue (ttm) | 141.93K USD |
| Revenue Per Share (ttm) | 0.006 USD |
| Quarterly Revenue Growth (yoy) | 40.20% |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -17891332 USD |
| Diluted EPS (ttm) | -0.64 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 25.72M USD |
| Total Cash Per Share (mrq) | 0.83 USD |
| Total Debt (mrq) | 325.01K USD |
| Total Debt/Equity (mrq) | 1.28 USD |
| Current Ratio (mrq) | 10.37 |
| Book Value Per Share (mrq) | 0.815 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -19389036 USD |
| Levered Free Cash Flow (ttm) | -13145111 USD |
Profile of Inhibikase Therapeutics
| Country | United States |
| State | GA |
| City | Atlanta |
| Address | 3350 Riverwood Parkway SE |
| ZIP | 30339 |
| Phone | (678) 392-3419 |
| Website | https://www.inhibikase.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 6 |
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Q&A For Inhibikase Therapeutics Stock
What is a current IKT stock price?
Inhibikase Therapeutics IKT stock price today per share is 2.15 USD.
How to purchase Inhibikase Therapeutics stock?
You can buy IKT shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Inhibikase Therapeutics?
The stock symbol or ticker of Inhibikase Therapeutics is IKT.
Which industry does the Inhibikase Therapeutics company belong to?
The Inhibikase Therapeutics industry is Biotechnology.
How many shares does Inhibikase Therapeutics have in circulation?
The max supply of Inhibikase Therapeutics shares is 74.34M.
What is Inhibikase Therapeutics Price to Earnings Ratio (PE Ratio)?
Inhibikase Therapeutics PE Ratio is now.
What was Inhibikase Therapeutics earnings per share over the trailing 12 months (TTM)?
Inhibikase Therapeutics EPS is -1.16 USD over the trailing 12 months.
Which sector does the Inhibikase Therapeutics company belong to?
The Inhibikase Therapeutics sector is Healthcare.
Inhibikase Therapeutics IKT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17368.02 USD — |
+0.01
|
7.42B USD — | 17256.2 USD — | 17422.89 USD — | — - | 7.42B USD — |
| NASDAQ HealthCare IXHC | 931.78 USD — |
+0.08
|
— — | 922.07 USD — | 931.8 USD — | — - | — — |
- {{ link.label }} {{link}}